Candel Therapeutics, INC 8-K filings

Candel Therapeutics has amended its bylaws to lower the quorum requirement for stockholder meetings from a majority to one-third of voting shares, effective May 29, 2024.

Candel Therapeutics announced positive topline data from its Phase 2 trial of CAN-2409, showing a significant increase in overall survival for lung cancer patients who did not respond to prior immunotherapy.

Candel Therapeutics reported positive survival data from a phase 2 trial of CAN-2409 in pancreatic cancer and announced first quarter 2024 financial results.

Candel Therapeutics will present data on its CAN-3110 and CAN-2409 cancer immunotherapies at the 2024 ASCO Annual Meeting, showcasing progress in treating recurrent high-grade glioma and non-small cell lung cancer.

Candel Therapeutics has been granted Orphan Drug Designation by the FDA for its CAN-2409 therapy for the treatment of pancreatic cancer.

Candel Therapeutics has unveiled a second immunotherapy candidate from its enLIGHTEN Discovery Platform, designed to induce tertiary lymphoid structures in solid tumors, with preclinical data showing promising results.

Candel Therapeutics reports significantly improved survival rates in patients with pancreatic cancer treated with CAN-2409 in a Phase 2 clinical trial.

Candel Therapeutics announced its full year 2023 financial results and provided updates on its clinical programs, including upcoming data readouts and FDA Fast Track Designations.

Candel Therapeutics will present a poster on a new multimodal immunotherapy candidate at the American Association for Cancer Research Annual Meeting in April.

Candel Therapeutics' CAN-3110, a novel oncolytic viral immunotherapy, has been granted Fast Track Designation by the FDA for the treatment of recurrent high-grade glioma.

Candel Therapeutics has appointed Charles Schoch as interim Chief Financial Officer, effective January 12, 2024, following the resignation of Jason A. Amello.